Bank of Hawaii Has $5.07 Million Stake in Natera, Inc. (NASDAQ:NTRA)

Bank of Hawaii reduced its position in Natera, Inc. (NASDAQ:NTRA - Free Report) by 8.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 32,032 shares of the medical research company's stock after selling 2,822 shares during the quarter. Bank of Hawaii's holdings in Natera were worth $5,071,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Blue Trust Inc. lifted its holdings in shares of Natera by 104.3% in the 4th quarter. Blue Trust Inc. now owns 190 shares of the medical research company's stock worth $30,000 after purchasing an additional 97 shares during the last quarter. Versant Capital Management Inc lifted its stake in Natera by 345.8% in the fourth quarter. Versant Capital Management Inc now owns 214 shares of the medical research company's stock valued at $34,000 after buying an additional 166 shares during the last quarter. EverSource Wealth Advisors LLC boosted its holdings in shares of Natera by 372.9% during the fourth quarter. EverSource Wealth Advisors LLC now owns 331 shares of the medical research company's stock valued at $52,000 after acquiring an additional 261 shares during the period. Principal Securities Inc. grew its position in shares of Natera by 20.7% during the fourth quarter. Principal Securities Inc. now owns 344 shares of the medical research company's stock worth $54,000 after acquiring an additional 59 shares during the last quarter. Finally, Steward Partners Investment Advisory LLC increased its holdings in shares of Natera by 1,328.0% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 357 shares of the medical research company's stock worth $57,000 after acquiring an additional 332 shares during the period. Institutional investors and hedge funds own 99.90% of the company's stock.

Remove Ads

Natera Trading Up 0.3 %

Shares of NTRA traded up $0.41 during midday trading on Monday, hitting $148.45. The stock had a trading volume of 873,690 shares, compared to its average volume of 1,394,376. Natera, Inc. has a fifty-two week low of $83.13 and a fifty-two week high of $183.00. The business has a 50-day simple moving average of $152.66 and a two-hundred day simple moving average of $152.24. The company has a current ratio of 4.39, a quick ratio of 4.23 and a debt-to-equity ratio of 0.33. The firm has a market cap of $20.07 billion, a P/E ratio of -84.35 and a beta of 1.80.

Natera (NASDAQ:NTRA - Get Free Report) last announced its earnings results on Thursday, February 27th. The medical research company reported ($0.41) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.42) by $0.01. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The company had revenue of $476.10 million for the quarter, compared to the consensus estimate of $447.91 million. As a group, equities analysts forecast that Natera, Inc. will post -1.49 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages have commented on NTRA. BTIG Research restated a "buy" rating on shares of Natera in a research note on Friday, February 28th. Canaccord Genuity Group restated a "buy" rating and issued a $180.00 target price on shares of Natera in a research report on Wednesday, February 26th. Sanford C. Bernstein boosted their price target on Natera from $160.00 to $200.00 and gave the stock an "outperform" rating in a research report on Friday, January 10th. StockNews.com raised Natera from a "sell" rating to a "hold" rating in a report on Wednesday, March 19th. Finally, Robert W. Baird lifted their price objective on shares of Natera from $183.00 to $188.00 and gave the company an "outperform" rating in a research note on Friday, February 28th. One analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $175.76.

Insider Buying and Selling at Natera

In related news, CEO Steven Leonard Chapman sold 78,553 shares of the stock in a transaction that occurred on Wednesday, January 22nd. The stock was sold at an average price of $164.97, for a total value of $12,958,888.41. Following the transaction, the chief executive officer now owns 267,629 shares in the company, valued at approximately $44,150,756.13. This represents a 22.69 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Solomon Moshkevich sold 24,861 shares of the firm's stock in a transaction that occurred on Wednesday, January 22nd. The shares were sold at an average price of $164.97, for a total transaction of $4,101,319.17. Following the transaction, the insider now directly owns 140,684 shares in the company, valued at approximately $23,208,639.48. The trade was a 15.02 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 325,922 shares of company stock valued at $51,603,664 in the last quarter. Company insiders own 7.60% of the company's stock.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.